Avenue Supermarts, which runs the DMart chain, has started a pilot program offering a flat 20% discount on medicines at select Mumbai stores. Through its subsidiary Reflect Healthcare and Retail Private Limited, the company aims to enter the high-margin pharmacy sector by using its existing store space. This move increases competition for neighborhood pharmacies and online drug retailers.
Avenue Supermarts, the operator of the popular DMart supermarket chain, has officially entered the pharmacy retail market. The company is currently running a pilot program at select stores in the Mumbai Metropolitan Region. This new service is being managed by its wholly owned subsidiary, Reflect Healthcare and Retail Private Limited, and features a flat 20% discount on all medicines.
The Shop-in-Shop Model
Instead of opening new, separate stores, DMart is using a shop-in-shop strategy. By placing pharmacy counters inside its existing high-footfall hypermarkets, the company avoids the heavy costs of buying or renting new real estate. This approach also allows DMart to gain immediate access to its large, existing customer base without spending extra money on marketing or customer acquisition. The company is applying its signature everyday-low-pricing model to this new category, which is a significant change for the pharmacy retail sector.
Financial and Competitive Implications
The pharmaceutical retail business typically offers higher gross margins, often between 25% and 30% for branded generic medicines, compared to the 7% to 8% operating profit margins DMart earns from its core grocery business. While these higher margins are attractive, they come with operational complexities. Running a pharmacy requires managing thousands of different stock-keeping units, which are specific items like medicines or health products, to ensure that customers can find exactly what they need in one visit.
Investors may note that the pharmaceutical supply chain in India is highly fragmented, involving many different manufacturers and distributors. Success in this area will depend on how efficiently the company can manage inventory and handle the logistics of a wide range of medications. Industry observers have pointed out that while the 20% discount is aggressive, the long-term profitability of such a model will depend on maintaining high sales volumes while managing the costs of a specialized supply chain.
Monitoring Future Progress
For investors, the key factor to watch will be the results of this pilot program. The company has not yet provided a timeline for a wider nationwide rollout. The success of this move will depend on whether DMart can maintain its high store efficiency while navigating the stricter regulatory and inventory requirements of the pharmacy business. Market watchers will likely track how local pharmacy owners and large online pharmacy players respond to this increased price competition. Future updates on store-level performance, the speed of expansion, and the impact on the company's overall profit margins will be important indicators of whether this new segment can successfully scale.